BLDpharm

A leading research chemicals manufacturer especially in building blocks.
ISO 9001 | 14001 | 45001 certificated DUNS registered.
[email protected]

[BLDpharm @BldPharm]

#BLDSynthesis 🧪 From FDA-Approved Gadoquatrane: DOTAs

Gadoquatrane (drug name: Ambelvist) is a next-generation intravenous macrocyclic gadolinium-based contrast agent approved by the U.S. FDA in June 2026 for contrast-enhanced MRI. It is indicated for detecting and visualizing lesions with abnormal vascularity in the central nervous system and non-CNS body regions in adults and pediatric patients, including term neonates. Featuring a novel tetrameric structure and high relaxivity, gadoquatrane provides effective imaging at the lowest approved gadolinium dose among U.S. macrocyclic GBCAs.
📰 https://t.co/A3ISHbv6Kh

Gadoquatrane is a tetrameric gadolinium-based contrast agent composed of four gadolinium ions, each tightly coordinated by a macrocyclic chelator derived from DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid). DOTA plays a critical role in the molecule by providing exceptional thermodynamic stability and kinetic inertness, which help minimize gadolinium release. The tetrameric architecture also contributes to the high relaxivity of gadoquatrane, enabling effective imaging at a reduced gadolinium dose.

👇 Try @BldPharm's DOTAs in your research！
https://t.co/g8EhKeJTBJ

#Gadoquatrane #FDA #DOTA

[BLDpharm @BldPharm]

#BLDSynthesis 🧪 From NMPA-Approved Conteltinib: 6,7-Dihydro-5H-pyrrolo[2,3-d]pyrimidines

Conteltinib (drug name: 首要泽) is a novel anaplastic lymphoma kinase (ALK) inhibitor developed by Shouyao Holdings (Beijing) Co., Ltd. and approved by China’s National Medical Products Administration (NMPA). It is indicated as monotherapy for patients with ALK-positive, locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously received ALK-targeted therapy.
📰 https://t.co/O93eUxqkju

Conteltinib incorporates the 6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine scaffold, a partially saturated fused pyrrolopyrimidine framework. Compared with fully aromatic pyrrolopyrimidines, this semi-saturated bicyclic motif provides increased three-dimensionality and conformational flexibility while retaining the favorable hydrogen-bonding characteristics of the pyrimidine ring. These features can enhance target selectivity and optimize physicochemical properties, making it an attractive scaffold for medicinal chemistry and kinase inhibitor design.

👇 Try @BldPharm's 6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidines in your research!
https://t.co/ZGbgQL40Pj

#NMPA #Conteltinib #ALK #NSCLC

[BLDpharm @BldPharm]

#BLDseries | 3,9-diazaspiro[5.5]undecane
Proteolysis-targeting chimera (PROTAC) technology has emerged as a promising therapeutic strategy capable of modulating both the catalytic and nonenzymatic functions of target proteins. PROTACs are heterobifunctional molecules composed of three key elements: a ligand for the protein of interest (POI), an E3 ligase ligand, and a linker connecting these two moieties. Among various linker designs, 3,9-diazaspiro[5.5]undecane has attracted increasing attention as a rigid spirocyclic linker scaffold. Recent studies reported in the Journal of Medicinal Chemistry (📰https://t.co/TTVvUMWvjf) demonstrated that replacing conventional flexible ether linkers with the more conformationally constrained 3,9-diazaspiro[5.5]undecane scaffold significantly improved PROTAC performance, leading to enhanced degradation activity (DC50 = 3.2 nM) and improved metabolic stability (T1/2 = 596 min). These findings highlight the potential of diazaspirocyclic linkers in optimizing PROTAC pharmacological properties.

👇 Try @BldPharm's 3,9-diazaspiro[5.5]undecanes in your research！
https://t.co/yGW1c11DN0

[BLDpharm @BldPharm]

#BLDSynthesis 🧪 From NMPA-Approved Rocbrutinib: Boc-Protected 3-Substituted Piperazine Building Blocks

Rocbrutinib (drug name: 麓可达) is a novel Class 1 targeted therapy developed by Guangzhou Lupeng Pharmaceutical. It is an oral, highly selective Bruton’s tyrosine kinase (BTK) inhibitor approved in China for adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have received at least two prior systemic therapies, including a BTK inhibitor. Approved through a priority review and conditional approval pathway, Rocbrutinib offers a new treatment option for patients with limited therapeutic choices and unmet clinical needs.
📰 https://t.co/v1bockZyvn

Boc-protected 3-substituted piperazine is a key intermediate in the synthesis of Rocbrutinib. The Boc group provides excellent protection and handling properties, while the 3-substituted piperazine core serves as an important structural motif in the target molecule. This building block offers high synthetic versatility, facilitating efficient downstream functionalization and process optimization.

👇 Try @BldPharm's Boc-protected 3-substituted piperazine building blocks in your research！
https://t.co/X3ArEppecD

#NMPA #Rocbrutinib #Piperazine

[BLDpharm @BldPharm]

@nippleointment 2-Octylcyclopropanecarboxylic acid exhibits a distinctive frankincense-like odor that is indeed very pleasant. 😍（https://t.co/yOYMhNg4Uk）

[BLDpharm @BldPharm]

#BLDseries | Arylcyclopropyl Carboxylic Acids
Arylcyclopropyl carboxylic acid is a versatile and high-value building block widely used in modern pharmaceutical research. This unique scaffold is present in several advanced drug candidates and approved molecules, including RTI-13951-33, Lemborexant, and Beclabuvir, highlighting its importance in medicinal chemistry. Its rigid cyclopropyl structure enhances metabolic stability and binding affinity, making it ideal for drug design and optimization.

👇 Try @BldPharm's arylcyclopropyl carboxylic acids in your research!
https://t.co/cuEtcTrGF5

[BLDpharm @BldPharm]

#BLDSynthesis | From FDA-Approved Zidebactam: Alicyclic hydrazides
Zaynich is a novel antibiotic developed by Wockhardt, an Indian pharmaceutical company. Combining cefepime and zidebactam, it was approved by FDA on May 29, 2026, for the treatment of complicated urinary tract infections (cUTIs), including pyelonephritis, caused by susceptible microorganisms. The drug is designed to address infections caused by multidrug-resistant Gram-negative bacteria, including so-called “superbugs” that are resistant to many existing antibiotics.
📰 https://t.co/ZPnuNwdMkK

Zidebactam contains an alicyclic hydrazide motif, a versatile functional group found in a variety of bioactive molecules. Alicyclic hydrazides are valuable intermediates in medicinal chemistry, enabling the construction of diverse molecular frameworks and supporting the development of new therapeutic candidates across multiple research areas.

👇 Try @BldPharm's alicyclic hydrazides in your research！
https://t.co/ijKPpqFrS7

#Alicyclic #Hydrazide #FDA #Zidebactam #Zaynich

[BLDpharm @BldPharm]

#BLDseries | Hexahydropyridazine-3-carboxylic acids
Revolution Medicines has disclosed several small-molecule programs across different stages of development, including daraxonrasib (RMC-6236), elironrasib (RMC-6291), zoldonrasib (RMC-9805), and earlier-stage assets such as RMC-5127 and RMC-7977. These compounds, targeting various KRAS mutations and the broader RAS signaling pathway, reflect a focused and consistent medicinal chemistry strategy evident in their published structures.
📰 https://t.co/M6GG3uXaRi

A notable common feature across many of these molecules is the hexahydropyridazine-3-carboxylic acid core. This scaffold contributes to key molecular properties and has become an important structural element in the design of RAS pathway inhibitors.

@BldPharm offers access to a broad range of hexahydropyridazine-3-carboxylic acid derivatives, supported by strong capabilities in custom synthesis and structural optimization. 
👇
https://t.co/zGnJsQzjv0

[BLDpharm @BldPharm]

#BLDSynthesis | From NMPA-Approved Fazamorexant: 8-azabicyclo[3.2.1]octanes
The National Medical Products Administration (NMPA) of China has approved Fazamorexant tablets (brand name: 孟平), a Class 1 innovative drug submitted by Jiangsu Haian Pharmaceutical Co., Ltd., a subsidiary of Yangtze River Pharmaceutical Group. The drug is indicated for the treatment of adult patients with insomnia characterized by difficulties in sleep initiation and/or sleep maintenance.

Fazamorexant (YZJ-1139) features the privileged bridged bicyclic scaffold 8-azabicyclo[3.2.1]octane, an important structural motif widely recognized in modern medicinal chemistry. This rigid nitrogen-containing framework provides well-defined three-dimensional geometry, favorable conformational restriction, and excellent opportunities for receptor binding optimization, making it highly valuable in central nervous system drug discovery.

👇 Try @BldPharm's 8-azabicyclo[3.2.1]octanes in your research！
https://t.co/zV5RH5FeMo

#Fazamorexant #NMPA #bicyclic #ChemicalBuildingBlocks

[BLDpharm @BldPharm]

#BLDseries | 3-Azabicyclo[3.1.0]hexane
3-Azabicyclo[3.1.0]hexane is a nitrogen-containing bicyclic scaffold composed of a five-membered ring fused with a three-membered ring. This rigid and compact structure appears in multiple drug candidates, including Zilurgisertib (ALK2 inhibitor), Nirmatrelvir (SARS-CoV-2 3CLpro inhibitor), PF-06835919 (KHK inhibitor), Iclepertin (GlyT1 inhibitor), and Boceprevir (NS3/NS4A inhibitor). Its unique three-dimensionality enhances binding interactions and physicochemical properties.

👇 Try @BldPharm's 3-Azabicyclo[3.1.0]hexanes in your research！
https://t.co/5rGYgcx4c9

[BLDpharm @BldPharm]

#BLDSynthesis🧪From FDA-Approved Baxdrostat: 5,6,7,8-Tetrahydroisoquinolines

Baxfendy® (baxdrostat) was approved by the FDA on May 15, 2026, for the treatment of hypertension in combination with other antihypertensive drugs.

Baxdrostat contains the 5,6,7,8-Tetrahydroisoquinoline scaffold, an important nitrogen-containing heterocyclic structure widely used in medicinal chemistry. This bicyclic motif offers excellent structural versatility, favorable binding properties, and broad potential for the design of bioactive pharmaceutical compounds.

👇Try @BldPharm's 5,6,7,8-tetrahydroisoquinolines in your research！
https://t.co/RC4gcCV6nY

#FDA #Baxdrostat #Tetrahydroisoquinoline

[BLDpharm @BldPharm]

#BLDevents 📍 We are happy to announce that BLDpharm will be a sponsor of the SCF 2026 Congress in Bordeaux!
Our team member will be present at this prestigious triennial congress. We invite all researchers to visit our booth 7️⃣ to explore collaboration opportunities.

#SCF2026 #Chemistry #UniversityBordeaux #FutureOfChemistry

[BLDpharm @BldPharm]

#BLDseries | Bridged Bicyclic Carboxylic Acids

Bridged bicyclic carboxylic acids are compounds in which a carboxyl group is incorporated onto a rigid bridged framework, combining well-defined three-dimensional geometry with versatile chemical reactivity. The inherent rigidity of these scaffolds enables precise spatial orientation of substituents, while the carboxylic acid functionality serves as a valuable handle for derivatization, including amide and ester formation. As a result, these molecules are important intermediates in synthetic and medicinal chemistry. Moreover, they can act as bioisosteres and contribute to improved physicochemical properties, such as solubility, polarity, and metabolic stability, making them attractive motifs in the design of novel drug candidates.

👇Try @BldPharm's bridged bicyclic carboxylic acids in your research!
https://t.co/vVPVZ2UTQi

[BLDpharm @BldPharm]

#BLDseries | Aryl cyclopropylamine
Aryl cyclopropylamine has emerged as a valuable building block in modern drug discovery. Broadly, cyclopropylamine can serve as a bioisostere of the amide bond, providing an effective approach to improve ADME properties while maintaining key biological interactions. This makes it a useful strategy for optimizing drug-like characteristics in lead compounds.

The importance of this scaffold is reflected in several drug candidates and marketed agents. For example, Pazufloxacin (an antimicrobial), BMS-929075 (an HCV NS5B allosteric inhibitor), and AZD7624 (a p38 inhibitor) all incorporate aryl cyclopropylamine motifs.

👇 Try @BldPharm's Aryl cyclopropylamines in your research!
https://t.co/30IoSFC77C

[BLDpharm @BldPharm]

#BLDseries | Amide Bond Bioisosteres: Trifluoroethylamine

Trifluoroethylamine is a useful amide bond bioisostere that lowers the basicity of the NH group while maintaining its hydrogen bond donor ability. It preserves a geometry similar to the planar amide bond (around 120°) and mimics features of the tetrahedral transition state in proteolysis. Additionally, the C–CF₃ bond exhibits electronic similarity to a carbonyl group, allowing it to substitute for amides in certain molecular designs.

Replacement of an amide bond with trifluoroethylamine was applied during the screening of VEGFR2 inhibitors based on a malonamide scaffold. While substitution at different positions led to varied effects on activity, this modification helped probe structure–activity relationships by balancing steric and hydrogen bonding features. In particular, certain derivatives retained strong VEGFR2 inhibitory potency and selectivity, despite reduced c-Met activity in some cases. Overall, incorporation of trifluoroethylamine proved to be a valuable strategy in the optimization and identification of potent VEGFR2 inhibitors.
📰https://t.co/VHEsvAR2vc

👇Try @BldPharm's building blocks in your research!
https://t.co/zYKyxm51ka

#Bioisosteres #Amide #Trifluoroethylamine

[BLDpharm @BldPharm]

#BLDseries | Thiazolo[5,4-b]pyridine
Thiazolo[5,4-b]pyridine is a fused heterocyclic scaffold consisting of a thiazole ring and a pyridine ring. Due to its rigid structure and the presence of nitrogen and sulfur atoms, it can form diverse interactions with biological targets, making it a valuable building block in medicinal chemistry. This motif has been widely used in the design of bioactive molecules.

Several reported compounds, such as Takeda-6D (BRAF/VEGFR2 inhibitor), AMG-369 (S1P1/S1P5 agonist), HG-7-85-01 (type II ATP-competitive inhibitor), and PC190723 (FtsZ inhibitor), contain the Thiazolo[5,4-b]pyridine core.

👇 Try @BldPharm's building blocks in your research!
https://t.co/P1V22gOQqN

#Thiazole #Pyridine #DrugDiscovery #MedicinalChemistry

[BLDpharm @BldPharm]

#BLDseries | 4,5-dihydro-1H-benzo[b]azepin-2(3H)-one scaffold

The 4,5-dihydro-1H-benzo[b]azepin-2(3H)-one scaffold is a benzazepinone framework formed by a benzene ring fused to a seven-membered azepine ring containing a single nitrogen atom. This bicyclic structure provides a relatively rigid core while allowing functional modifications at several positions, which makes it useful in medicinal chemistry.

For example, γ-secretase inhibitor LY-411575, the growth hormone secretagogue receptor agonist MK-0751, the ACE inhibitor benazepril, the CDK inhibitor alsterpaullone, and the endothelin-converting enzyme inhibitor daglutril. These molecules illustrate the broad pharmacological potential of this scaffold.

👇Try @BldPharm 's building blocks in your research！
https://t.co/msxQQUBhDT

#Azepine #DrugDiscovery #MedicinalChemistry

[BLDpharm @BldPharm]

#BLDSynthesis | From NMPA-Approved Sevabertinib: Hydroxymethyl-containing aliphatic heterocycles
Sevabertinib (drug name: 赫新诺) is a novel Class 1 innovative drug recently approved by China’s National Medical Products Administration (NMPA) under a priority review pathway in April 15, 2026. Developed by Bayer HealthCare Pharmaceuticals Inc., it is indicated as a monotherapy for adult patients with unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring HER2 (ERBB2) activating mutations, who have previously received at least one systemic treatment.
📰 https://t.co/8BPH5EVdf6

Sevabertinib incorporates a hydroxymethyl-containing aliphatic heterocycle, highlighting the value of this motif in drug design. Such building blocks can enhance solubility, optimize pharmacokinetics, and support precise target interactions, making them attractive components for developing innovative small-molecule therapeutics.

Try @BldPharm's hydroxymethyl-containing aliphatic heterocycles in your research!👇
https://t.co/3AyKU0DO7F

#Hydroxymethyl #NMPA #Sevabertinib #AliphaticHeterocycles